Home › Funds › Davern Capital Partners, LP › REGN
Davern Capital Partners, LP position in REGN
REGENERON PHARMACEUTICALS · Health Care
Davern Capital Partners, LP reported holding 40,661 shares of REGN (REGENERON PHARMACEUTICALS) in its Q3 2026 13F filing — a position valued at US$30.8M, representing 6.00% of its reported portfolio and ranking #7 among its reported holdings. Davern Capital Partners, LP has disclosed REGN holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-12 · Source: SEC EDGAR Form 13F-HR
How Davern Capital Partners, LP's REGN position evolved
Davern Capital Partners, LP first disclosed a stake in REGN in Q4 2025 at 52,420 shares (US$40.5M). The position peaked in Q2 2026 at 92,640 shares, worth US$57.8M. Across 4 filings, Davern Capital Partners, LP increased the stake 1 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 40,661 shares valued at US$30.8M — a reduction of -51,979 shares quarter over quarter.. Notable position changes include a 107% increase in Q2 2026 (shares rose 22% over the following quarter), a 56% trim in Q3 2026 (shares rose 27% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 52.42K | $40.46M | New |
| Q1 2026 | 44.80K | $34.61M | Reduce |
| Q2 2026 | 92.64K | $57.76M | Add |
| Q3 2026 | 40.66K | $30.83M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About REGN and 13F data
REGN (REGENERON PHARMACEUTICALS) is a Health Care company. 30 other funds we track also report a position in REGN — the largest reported positions include Dodge & Cox (US$3.04B), DODGE & COX (US$3.04B), Nuveen, LLC (US$1.48B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding REGN
- Dodge & Cox 4.87M sh · $3.04B · Q2 2026
- DODGE & COX 4.87M sh · $3.04B · Q2 2026
- Nuveen, LLC 1.96M sh · $1.48B · Q3 2026
- LOOMIS SAYLES & CO L P 1.86M sh · $1.16B · Q2 2026
More on Davern Capital Partners, LP
FAQ
How long has Davern Capital Partners, LP held REGN?
Davern Capital Partners, LP has disclosed REGN holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Davern Capital Partners, LP's current position in REGN?
As of Q3 2026, Davern Capital Partners, LP holds 40.66K shares of REGN (REGENERON PHARMACEUTICALS), valued at $30.83M, representing 6.00% of its reported portfolio and ranking #7.
Has Davern Capital Partners, LP been buying or selling REGN?
In the latest 13F filing (Q3 2026), Davern Capital Partners, LP reduced its position in REGN. The position peaked in Q2 2026 at 92.64K shares.
Which other funds hold REGN?
Other major institutional holders of REGN include Dodge & Cox, DODGE & COX, Nuveen, LLC, among 30 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.